anti-PD-1 monoclonal antibody + platinum + pemetrexed

This combination regimen is a standard-of-care chemo-immunotherapy for the first-line treatment of non-squamous non-small cell lung cancer (NSCLC). It comprises an anti-PD-1 monoclonal antibody (such as tislelizumab), a platinum-based chemotherapy agent (cisplatin or carboplatin), and pemetrexed (an antifolate antineoplastic agent). The regimen functions by simultaneously stimulating the immune system's anti-tumor response through PD-1 inhibition and inducing direct cytotoxic effects on cancer cells by interfering with DNA synthesis and repair. In the context of InxMed (Shanghai) Co., Ltd.'s clinical development, this triplet therapy serves as the active control arm in a Phase 3 trial evaluating the dual-oral combination of ifebemtinib (IN10018) and garsorasib (D-1553) for KRAS G12C-mutant non-squamous NSCLC.

Other names

anti-PD-1 monoclonal antibody + platinum + pemetrexedtislelizumab + platinum + pemetrexedstandard chemo-immunotherapy